Cargando…

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rachiglio, Anna Maria, Abate, Riziero Esposito, Sacco, Alessandra, Pasquale, Raffaella, Fenizia, Francesca, Lambiase, Matilde, Morabito, Alessandro, Montanino, Agnese, Rocco, Gaetano, Romano, Carmen, Nappi, Anna, Iaffaioli, Rosario Vincenzo, Tatangelo, Fabiana, Botti, Gerardo, Ciardiello, Fortunato, Maiello, Monica R., De Luca, Antonella, Normanno, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341823/ https://www.ncbi.nlm.nih.gov/pubmed/27448974 http://dx.doi.org/10.18632/oncotarget.10704

Ejemplares similares

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine
por: Dotolo, Serena, et al.
Publicado: (2021)

Challenges in bioinformatics approaches to tumor mutation burden analysis
por: Fenizia, Francesca, et al.
Publicado: (2021)

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
por: De Luca, Antonella, et al.
Publicado: (2020)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
por: Pasquale, Raffaella, et al.
Publicado: (2020)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology
por: Roma, Cristin, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2020)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022)

External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme
por: Esposito Abate, Riziero, et al.
Publicado: (2022)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
por: Normanno, Nicola, et al.
Publicado: (2011)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Angiogenesis Inhibitors in Small Cell Lung Cancer
por: Montanino, Agnese, et al.
Publicado: (2021)

European Real-World Assessment of the Clinical Validity of a CE-IVD Panel for Ultra-Fast Next-Generation Sequencing in Solid Tumors
por: Normanno, Nicola, et al.
Publicado: (2023)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system
por: Rachiglio, Anna Maria, et al.
Publicado: (2021)

Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel
por: Scarpa, Aldo, et al.
Publicado: (2013)

Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
por: Esposito Abate, Riziero, et al.
Publicado: (2019)

AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015)

Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice
por: Dotolo, Serena, et al.
Publicado: (2022)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
por: Ciardiello, Davide, et al.
Publicado: (2022)

Immunotherapy in Small Cell Lung Cancer
por: Esposito, Giovanna, et al.
Publicado: (2020)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
por: Martinelli, E, et al.
Publicado: (2017)

Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
por: Sacco, Alessandra, et al.
Publicado: (2020)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Duodenal gangliocytic paraganglioma, a rare entity among GEP-NET: a case report with immunohistochemical and molecular study
por: Tatangelo, Fabiana, et al.
Publicado: (2014)

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial
por: Avallone, Antonio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_741dkf1pj9p332adup19fdgsdn